| |||
| |||
| |||
| |||
| |||
| |||
| |||
| |||
Patrick Trucchio, H.C. Wainwright & Co.(6/30/22) |
|||
|
|||
Patrick Trucchio, H.C. Wainwright & Co.(5/2/22) |
|||
|
|||
Andrew Partheniou, Stifel(3/31/22) |
|||
|
|||
Patrick Trucchio, H.C. Wainwright & Co.(2/1/22) |
|||
|
|||
![]() |
Jason McCarthy, Maxim Group(9/1/21) |
||
|
Clive Maund – CliveMaund.com | |
![]() |
Jason McCarthy, Analyst – Maxim Group |
Andrew Partheniou – Stifel | |
Matthew Pepler, Analyst – Canaccord Genuity | |
Patrick Trucchio, Analyst – H.C. Wainwright & Co. |
8/15/2022 – Revitalist Partners with Awakn Life Sciences as First Licensee in the United States to begin Redefining Treatment for Addiction, Recovery, and Relapse Prevention in the Psychedelic Space
7/20/2022 – Awakn Life Sciences' Phase III Trial Approved for Approximately CA$2.5 Million Funding from UK State Covering 66% of Costs
7/15/2022 – Awakn Life Sciences Provides a Business and Corporate Update
7/5/2022 – Awakn Life Sciences Receives UK State Funding to Identify Optimal Pathway to Market in UK & US for Its Lead Clinical Development Program - Ketamine-Assisted Therapy for Alcohol Use Disorder
The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.See disclaimer for more details.
Significant Market Opportunity: Alcohol Use Disorder treatment industry is large ($35bn US alone) but underperforming with low post treatment abstinence rates | |
Late Clinical Stage Lead Program: Successful phase IIb for Alcohol Use Disorder, achieving 86% abstinence for 6 months post treatment | |
Deep Pipeline Already Generating Revenue: Multiple opportunities for value creation through deep R&D pipeline and already generating revenue Awakn Clinics in the Europe |
![]() Q3 2022 |
R&D: Progress lead program into Phase III; securing grant from UK state for 66% of costs of phase II
|
![]() Q3 2022 |
Commercialisation: Enter North American market in Q4 ’22 through out-licencing agreements to 3rd par
|
![]() Q3 2022 |
Capital Markets: Targeted up list to Nasdaq in 2023
|